Dynavax Technologies Corporation (DVAX)

11,21 +0,04 (+0,36%) Al cierre: 04:00PM EDT

Dynavax Technologies Corporation

2100 Powell Street
Suite 720
EmeryVille, CA 94608
United States
510 848 5100
https://www.dynavax.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 408

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Ryan Spencer	CEO, Interim CFO & Director	1,49M	N/A	1978
Mr. David F. Novack	President & COO	1,01M	1,51M	1962
Dr. Robert Janssen M.D.	Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs	861,52k	251,32k	1954
Ms. Kelly MacDonald	Senior VP & CFO (Leave of Absence)	788,55k	N/A	1984
Mr. Justin Burgess	Chief Accounting Officer & Controller	N/A	N/A	N/A
Mr. Jeff P. Coon	Senior VP & Chief Human Resources Officer	N/A	N/A	1963
Mr. Paul Cox	VP of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. John L. Slebir	Senior VP & General Counsel	N/A	N/A	1966
Mr. Donn Casale	Senior VP & Chief Commercial Officer	N/A	N/A	N/A
Dr. Dong Yu	Senior Vice President of Vaccine Research	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Gobierno corporativo

El ISS Governance QualityScore de Dynavax Technologies Corporation, a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 5; Tablero: 5; Derechos de los accionistas: 7; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.